Riccardo founded the genetic vaccine company Okairos in 2007 and led the company through its successful acquisition by GSK in 2013. He continues to lead the related service and GMP manufacturing company in the field of infectious diseases, Keires AG in Basel.
Previously, Riccardo was the founder and head of the Istituto di Ricerche di Biologia Molecolare (IRBM) in Rome, Italy, which later became a subsidiary of Merck Inc. Before that, he established the Gene Expression Unit at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany.
Riccardo has been instrumental in the development of several novel antiviral drugs and vaccines, ranging from various stages of clinical development to fully marketed drugs, including Isentress® for HIV.
He has also published in leading scientific journals on immunology, molecular medicine and drug discovery.
Riccardo was a Professor of Molecular Biology at the medical school of the University of Naples, Italy, where he completed his medical degree before receiving his PhD from the University of California at Berkeley.